| The Babraham Institute Patent applications |
| Patent application number | Title | Published |
|---|
| 20120039905 | The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection - The invention includes compositions and methods for regulating p110 delta as an anti-influenza virus therapy. The invention includes inhibiting p110 delta, a component of p110 delta signaling pathway, or any combination thereof in a cell as an anti-influenza viral therapeutic approach for treating influenza virus infection. The invention includes a method of modulating p110 delta in a cell by contacting the cell with an effective amount of a composition comprising an inhibitor of p110 delta. | 02-16-2012 |
| 20110135655 | Role of PI3K p110 delta Signaling in Retroviral Infection and Replication - The invention includes compositions and methods for regulating PI3K p110 delta as an anti-retroviral therapy. The invention includes inhibiting p110 delta, a component of PI3K p110 delta signaling pathway, or any combination thereof in a cell as an anti-retroviral therapeutic approach for treating a retroviral infection, for example HIV. The invention includes a method of modulating PI3K p110 delta in a cell infected with a retrovirus by contacting the cell with an effective amount of a composition comprising an inhibitor of PI3K p110 delta. | 06-09-2011 |
| 20080274950 | Cell Adhesion by Modified Cadherin Molecules - The potential role of so called ‘cell adhesion recognition motifs’ (CARs) in cadherin adhesion has been emphasized. Due to the importance of cadherin binding in biological process, there remains a need to develop effective ways of manipulating cadherin adhesion. According to the present invention, there is provided a pair of cadherin molecules modified to enhance intermolecular adhesion (i.e. adhesion or binding between the pair of cadherin molecules) compared with corresponding unmodified cadherin molecules. Intermolecular adhesion between the cadherin molecules may be enhanced by reducing or eliminating intramolecular binding within each cadherin molecule. For example, intramolecular binding may be reduced or eliminated by diminishing or preventing intramolecular binding of an N-terminal binding strand of each cadherin molecule with a binding strand acceptor pocket of each cadherin molecule. Additionally or alternatively, the intramolecular binding may be reduced or eliminated by diminishing or preventing the formation of an intramolecular ionic bond between the NH2 terminus of each cadherin molecule with a contact acidic amino acid residue of each cadherin molecule. | 11-06-2008 |
